DOCSLIB.ORG

Drug Delivery Technology

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Drug Delivery Technology * DDT Nov-Dec 2006 Round 5 11/10/06 7:20 PM Page 2 November/December 2006 Vol 6 No 10 IN THIS ISSUE Corporate Profiles 16 Drug Delivery Technologies 73 Excipients, Polymers, Liposomes & Lipids 90 Contract Pharmaceutical & Biological Development Services 96 Machinery & Laboratory Equipment and Software 109 Technology Spotlight 114 The science & business of specialty pharma, biotechnology, and drug delivery www.drugdeliverytech.com * DDT Nov-Dec 2006 Round 5 11/10/06 7:22 PM Page 3 * DDT Nov-Dec 2006 Round 5 11/10/06 7:22 PM Page 4 * DDT Nov-Dec 2006 Round 5 11/10/06 7:22 PM Page 5 November/December 2006 Vol 6 No 10 PUBLISHER/PRESIDENT Ralph Vitaro EXECUTIVE EDITORIAL DIRECTOR Dan Marino, MSc [email protected] CREATIVE DIRECTOR Shalamar Q. Eagel CONTROLLER Debbie Carrillo CONTRIBUTING EDITORS Cindy H. Dubin Debra Bingham Jason McKinnie TECHNICAL OPERATIONS Mark Newland EDITORIAL SUPPORT Nicholas D. Vitaro ADMINISTRATIVE SUPPORT Kathleen Kenny Corporate/Editorial Office 219 Changebridge Road, Montville, NJ 07045 Tel: (973)299-1200 Fax: (973) 299-7937 www.drugdeliverytech.com Advertising Sales Offices East & Midwest Victoria Geis - Account Executive Cheryl S. Stratos - Account Executive 103 Oronoco Street, Suite 200 Alexandria, VA 22314 Tel: (703) 212-7735 Fax: (703) 548-3733 E-mail: [email protected] E-mail: [email protected] West Coast Warren De Graff Western Regional Manager 818 5th Avenue, Suite 301 San Rafael, CA 94901 Tel: (415) 721-0644 Fax: (415) 721-0665 E-mail: [email protected] International Ralph Vitaro 219 Changebridge Road Vol 6 No 10 Montville, NJ 07045 Tel: (973) 299-1200 Fax: (973) 299-7937 E-mail: [email protected] Mailing List Rental Candy Brecht Tel: (703) 706-0383 Fax: (703) 549-6057 E-mail: [email protected] All editorial submissions are handled with reasonable care, but the publishers assume no responsibility for the safety November/December 2006 of artwork, photographs, or manuscripts. Every precaution is taken to ensure accuracy, but publishers cannot accept responsibility for the accuracy of information supplied herein or for any opinion expressed. Drug Delivery Technology (ISSN 1537-2898) is published 10 times in 2006, January, February, March, April, May, June, July/August, September, October, and November/December by Drug Delivery Technology LLC, 219 Changebridge Road, Montville NJ 07045. Subscription rates: $99.00 for 1 year in the United States, Canada, and Mexico. $153.00 for 1 year outside the United States, Canada, and Mexico. All subscriptions are payable in US funds, drawn on US banks. Send payment to: Drug Delivery Technology LLC subscription Department, 219 Changebridge Road, Montville NJ 07045. Single copies (prepaid) $15.00, US, Canada, and Mexico; $24.00 in all other countries. Add $5.00 per order for shipping and handling. Periodicals Postage Paid at Montville, NJ 07045-9998 and additional mailing offices. Postmaster: please send address changes to Drug Delivery Technology, 219 Changebridge Road, Montville NJ 07045. All rights reserved under the U.S., International and Pan-American Copyright Conventions. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including by photocopy, recording, or information storage and retrieval system, without written permission from the publisher. Authorization to photocopy Drug Delivery Technology items for internal or personal use, or the internal or personal use of specific clients, is granted by Drug Delivery Technology LLC for libraries and other users registered with the Copywrite Clearance, 222 Rosewood Drive, Danvers, MA 01923; phone: (978) 750-8400, fax: (978) 750-4470. 4 * DDT Nov-Dec 2006 Round 5 11/10/06 7:22 PM Page 6 * DDT Nov-Dec 2006 Round 5 11/10/06 7:22 PM Page 7 Company Profiles 16 For each participating company, this section presents a special 2-page spread featuring core technologies, capabilities, products, and services as well as visuals and complete contact information. Featured companies include: 3M Drug Delivery Capsugel Hovione Systems Cardinal Health Huber Engineering ALZA Corporation Coating Place Iomed ASSA International Controlled Release Society Kurve Technologies BASF Degussa Lipocine Baxter BioPharma DPT Laboratories Loparex Inc. Solutions Drug Delivery Partnerships NOF Corporation BC Technology Eurand PharmaCircle Bespak ExcipientFest PharmaMed Device BD Filtertek Inc. RDD Europe BioScreen Testing Genzyme Pharmaceuticals Safety Syringes Service Glatt Pharmaceutical Services Scolr Pharma, Inc BioConvergence Halozyme Weiler Engineering Partnerships, Technologies & Pipeline Report 73 This Report, divided into four sections for Drug Delivery, Excipient, Contract Services, and Machinery & Laboratory Equipment & Software, provides a checklist of currently marketed technologies or services and Vol 6 No 10 their applications, pipeline/investigational technologies and their applications and stage of development, and partnerships. Technologies include: Oral Gene Therapy Rectal Inhalation Mucosal Vaginal Transdermal Capsules Colon November/December 2006 Parenteral Intranasal Liposomes Implants Polymers Lipids Nasal Biomaterials Devices Topical Proteins & Peptides Ocular Drug Delivery Technology Transmucosal Controlled Release Excipients 6 * DDT Nov-Dec 2006 Round 5 11/10/06 7:22 PM Page 8 * DDT Nov-Dec 2006 Round 5 11/10/06 7:23 PM Page 9 Drug Delivery Spotlight 114 To complement the Company Profiles and Special Report, this section examines innovative and emerging technologies, services, and devices, featuring dynamic 4-color visuals and contact information. Vol 6 No 10 November/December 2006 Drug Delivery Technology 8 * DDT Nov-Dec 2006 Round 5 11/10/06 7:23 PM Page 10 * DDT Nov-Dec 2006 Round 5 11/10/06 7:23 PM Page 11 Dan Marino, MSc Executive Editorial Director Drug Delivery Technology Jack Aurora, PhD John A. Bermingham Matthew D. Burke, PhD Director, Pharmaceutical President & CEO Investigator, Research & Development Ampad, LLC Pharmaceutical Development Pharmascience, Inc GlaxoSmithKline Sarath Chandar, MBA Mahesh Chaubal, Gary W. Cleary, PhD, Vice President, Global PhD, MS PharmD, MBA Marketing & Commercial Associate Director President & CTO Development Baxter Healthcare Corium International SPI Pharma Sonya Summerour James N. Czaban, JD John Fraher Clemmons, PhD, MBA, MS Attorney at Law President, North America Director, Business Heller Ehrman White & Eurand Development McAuliff, LLPP MediVas, LLC Philip Green, PhD Keith Horspool, PhD Ravi Kiron, PhD, MBA Executive Director, New Director of Business Director, Research Technology Assessment & Development Formulations Planning Advanced Drug Delivery Pfizer Global Research & ALZA Corporation BD Development David C. Klonoff, MD, FACP Uday B. Kompella, PhD James W. McGinity, PhD Clinical Professor of Associate Professor of Professor of Pharmaceutics Medicine - UC San Francisco Pharmaceutics University of Texas at Austin Medical Director University of Nebraska Mills-Peninsula Diabetes Medical Center Research Institute Nasser Nyamweya, PhD Kinam Park, PhD Philip L. Smith, PhD Technical Service Manager President Investment Manager Vol 6 No 10 6 No Vol Degussa Akina, Inc S.R. One, Limited, GlaxoSmithKline Ronald L. Smith, PhD Cornell Stamoran Tom Tice, PhD Director of Exploratory VP, Strategy & Business Executive Vice President Biopharmaceutics & Process and Chief Scientific Officer November/December 2006 November/December Drug Delivery Cardinal Health, PTS Brookwood Bristol-Myers Squibb Pharmaceuticals Research Institute James Vaughan Howard S. Wachtler Henry Y. Wu, PhD, MS General Manager President & CEO Associate Director 3M Drug Delivery Actinium Merck Research Drug Delivery Technology Drug Delivery Technology Systems Pharmaceuticals Laboratories 10 * DDT Nov-Dec 2006 Round 5 11/10/06 7:23 PM Page 12 * DDT Nov-Dec 2006 FINAL 11/14/06 12:58 PM Page 13 Tris Pharma Unveils Expansion of State-of-the-Art Research Facility ris Pharma, a privately owned specialty Tpharmaceutical company, recently unveiled a new state-of-the-art research and manufacturing facility at a South Brunswick, New Jersey, campus. These expanded capabilities are a result of the company’s success with its innovative drug delivery technologies. This 30,000-square-foot expansion adds a state- of-the-art, FDA-compliant cGMP facility and marks the transition of Tris Pharma to a technology firm that has all the capabilities, including manufacturing, in one facility. The company can provide its partners clinical supplies, submission batches, eCTD filing, and medium- scale commercial production of tablets, capsules, liquid suspensions, and oral solutions, and packaging for the finished products. “This facility enhances our manufacturing capabilities and also enables us to continue to invest in our drug development,” said Ketan Mehta, CEO and Founder of Tris Pharma. “This is the final piece of the puzzle for our first phase of growth and keeps our operations scalable to keep pace with several more deals and new technologies in the pipeline.” Tris Pharma envisioned a cutting-edge manufacturing facility and set out to build it. Rather than rely on outside contractors, the company hired top experts in the field to design and build the plant from scratch. The result is 15 cGMP suites that are completely flexible, with end-to-end in-built utilities and features that streamline the drug production process. The new facility also expands the company’s current capabilities by including
Load more

Recommended publications
  • Drug Delivery Technology Y
    * DDT Nov-Dec 2007 Working 11/9/07 2:29 PM Page 1 November/December 2007 Vol 7 No 10 IN THIS ISSUE Company Profiles 12 Drug Delivery Technologies 58 Excipients, Polymers, Liposomes & Lipids 78 Contract Pharmaceutical & Biological Development Services 83 Machinery & Laboratory Equipment and Software 96 Technology Showcase 102 The science & business of specialty pharma, biotechnology, and drug delivery www.drugdeliverytech.com * DDT Nov-Dec 2007 Working 11/9/07 2:39 PM Page 2 * DDT Nov-Dec 2007 Working 11/9/07 2:40 PM Page 3 * DDT Nov-Dec 2007 Working 11/9/07 2:40 PM Page 4 November/December 2007 Vol 7 No 10 PUBLISHER/PRESIDENT Ralph Vitaro EXECUTIVE EDITORIAL DIRECTOR Dan Marino, MSc [email protected] CREATIVE DIRECTOR Shalamar Q. Eagel CONTROLLER Debbie Carrillo CONTRIBUTING EDITORS Cindy H. Dubin Debra Bingham Jason McKinnie TECHNICAL OPERATIONS Mark Newland EDITORIAL SUPPORT Nicholas D. Vitaro ADMINISTRATIVE SUPPORT Kathleen Kenny Corporate/Editorial Office 219 Changebridge Road, Montville, NJ 07045 Tel: (973)299-1200 Fax: (973) 299-7937 www.drugdeliverytech.com Advertising Sales Offices East & Midwest Victoria Geis - Account Executive Coming in 2008 Cheryl S. Stratos - Account Executive 103 Oronoco Street, Suite 200 Alexandria, VA 22314 Tel: (703) 212-7735 Drug Delivery Weekly & Fax: (703) 548-3733 E-mail: [email protected] Specialty Pharma News E-mail: [email protected] West Coast Warren De Graff Western Regional Manager 818 5th Avenue, Suite 301 San Rafael, CA 94901 Tel: (415) 721-0644 Fax: (415) 721-0665 E-mail: [email protected] 0 The weekly electronic newsletter from the publishers of Drug 1 International o N Delivery Technology and Specialty Pharma will provide over 12,000 Ralph Vitaro 7 219 Changebridge Road l o subscribers with the latest news of business deals, alliances, and V Montville, NJ 07045 Tel: (973) 299-1200 7 technology breakthroughs from the pharmaceutical, specialty 0 Fax: (973) 299-7937 0 2 pharmaceutical, drug delivery, and biotechnology industries.
    [Show full text]
  • DDT Cover/Back April 2006.Qx
    June 2007 Vol 7 No 6 www.drugdeliverytech.com IN THIS ISSUE INTERVIEW WITH EURAND’S CHIEF COMMERCIAL OFFICER MR. JOHN FRAHER The eFlow® Nebulizer 30 Shabtai Bauer, PhD Markus Tservistas, PhD Bioadhesive Microspheres 54 Jayvadan Patel, PhD Transdermal Solutions 68 Gary W. Cleary, PhD FEATURING Imaging CROs 72 Richard Taranto Autoimmune The science & business of specialty pharma, biotechnology, and drug delivery Diseases 80 Douglas Kerr, MD Adam Kaplin, MD JuliaJulia Rashba-Rashba- Shaukat Ali, Richard Step,Step, PhDPhD PhD Sitz, MBA EfEfficientficient PulmonaryPulmonary HMW Povidone Beyond Sticky Partnering With DeliveryDelivery ofof BiologicalBiological PolymerPolymer-Based-Based toto Sophisticated:Sophisticated: NovaQuest 84 MoleculesMolecules asas Films for The Many PROMAXXPROMAXX Fast-Dissolving Dimensions Ms. Cindy H. Dubin MicrMicrospheresospheres Drug Delivery of Adhesives June 2007 Vol 7 No 6 PUBLISHER/PRESIDENT Ralph Vitaro EXECUTIVE EDITORIAL DIRECTOR Dan Marino, MSc [email protected] CREATIVE DIRECTOR Shalamar Q. Eagel CONTROLLER Debbie Carrillo CONTRIBUTING EDITORS Cindy H. Dubin Debra Bingham Jason McKinnie TECHNICAL OPERATIONS Mark Newland EDITORIAL SUPPORT Nicholas D. Vitaro ADMINISTRATIVE SUPPORT Kathleen Kenny Corporate/Editorial Office 219 Changebridge Road, Montville, NJ 07045 Tel: (973)299-1200 Fax: (973) 299-7937 www.drugdeliverytech.com Advertising Sales Offices East & Midwest Victoria Geis - Account Executive Cheryl S. Stratos - Account Executive 103 Oronoco Street, Suite 200 Alexandria, VA 22314 Tel:
    [Show full text]
  • Happy-Healthy-Hormones-Latest.Pdf
    HAPPY HEALTHY HORMONES Daved Rosensweet M.D. HOW TO THRIVE IN MENOPAUSE Daved Rosensweet M.D. HOW TO THRIVE IN MENOPAUSE HAPPY HEALTHY HORMONES Daved Rosensweet M.D. HOW TO THRIVE IN MENOPAUSE This book has been written and published to provide information and should not be used as a substitute for the recommendations of your health care professional. Be- cause each person and medical situation are unique, the reader is urged to review this information with a qualified health professional. You should not consider the infor- mation contained in this text to represent the practice of medicine or to replace consultation with a physician or other qualifiedhealth care provider. The Menopause Method, Inc. Sarasota, Florida 941-366-3768 www.menopausemethod.com [email protected] The Menopause Method: A Woman’s Guide to Navigating Menopause, sixth edition, 2017. Copyright © 2001, 2002, 2006, 2007, 2014, 2017 by Daved Rosensweet M.D. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photo- copying, recording, or otherwise, without the prior written permission of the copyright owner. Sixth Edition 2017 ISBN: 9780999744901 Published in the United States of America Dedication This book is dedicated, first and foremost, to my patients in menopause: for 24 years, woman by woman, moment by moment, molecule by molecule, you have given me what has culminated in these pages. You know who you are, and I do thank you. Writing this dedication has turned out to be a deep and heartfelt experience for me.
    [Show full text]
  • M1 Covered Drug List
    Metallic M1 - List of Covered Drugs (Formulary) Effective Date: 09-01-2021 The Metallic M1 Formulary is used by these plans: Plus HSA Qualified Bronze 5950 Plus HSA Qualified Gold 1500 Plus HSA Qualified Silver 2800 Plus HSA Qualified Silver 3500 Plus HSA Qualified Bronze 6900 What is the list of covered drugs (Formulary)? This document contains a list of generic, brand and specialty drugs covered under your plan. How is the list of covered drugs developed? The drug list is developed with an independent committee of physicians, pharmacists and other healthcare providers called the Pharmacy and Therapeutics Committee. This independent committee reviews and selects drugs for coverage based on each drugs safety, effectiveness and cost. The committee meets at least quarterly to review new drugs to market to determine placement on this list and also reviews updated safety, effectiveness and cost information for existing drugs to ensure the formulary remains up to date with current medical evidence. How do I use the Formulary? Drugs are listed by categories depending on the type of medical conditions that they are used to treat. If you know what your drug is used for, look for the category name in the list that begins below. Then look under the category name for your drug. If you are not sure what category to look under, you can also search for the drug in the Index. The Index provides an alphabetical list of all of the drugs included in this document. Next to the name of the drug in the Index, you will see the page number where you can find coverage information.
    [Show full text]
  • A Review on Transdermal Spray
    Review Article Mathews Journal of Pharmaceutical Science A Review on Transdermal Spray: Formulation Aspect Uttam Kumar Mandal1, Bappaditya Chatterjee1, Fatin Husna Binti Pauzi1 1Department of Pharmaceutical Technology, Kulliyyah of Pharmacy, International Islamic University Malaysia (IIUM), Kuantan, Malaysia. Corresponding Author: Uttam Kumar Mandal, Department of Pharmaceutical Technology, Kulliyyah of Pharmacy, International Islamic University Malaysia (IIUM), Bander Indera Mahkota, Kuantan 25200, Pahang, Malaysia. Tel: +6 0109062750; Email: [email protected] Received Date: 22 Feb 2016 Copyright © 2016 Mandal UK Accepted Date: 24 Mar 2016 Citation: Mandal UK (2016) A Review on Transdermal Spray: Published Date: 30 Mar 2016 Formulation Aspect. M J Pharma 1(1): 006. ABSTRACT Transdermal spray offers numerous advantages over the other conventional transdermal drug delivery forms such as gel, ointment and patches, in terms of its cosmeceutical appearance, ready availability for application, flexibility in dosage design, less occurrence of skin irritation and faster drying rate from the application site due to the use of volatile solvent. However, compared to other transdermal drug delivery dosage forms, transdermal spray has the least and limited num- ber of products approved for marketing. Among the drugs are, Evamist®, an estradiol formulation approved in 2007 by the FDA followed by Axiron® a non-spray solution to treat low testosterone in men and Recuvyra®, a pain reliever solution indicated for dogs. This review article focuses current status on the formulation and evaluation of transdermal spray in the background of the role and effects of its composition specially the selection of drugs, volatile solvents, penetration enhancers and film forming polymer, etc. The limitation of transdermal spray highlighted in this review is the concern of its use, especially, the third party exposure particularly for endocrinology indication.
    [Show full text]
  • Preparation and the Biopharmaceutical Evaluation for the Metered Dose Transdermal Spray of Dexketoprofen
    Hindawi Publishing Corporation Journal of Drug Delivery Volume 2014, Article ID 697434, 12 pages http://dx.doi.org/10.1155/2014/697434 Research Article Preparation and the Biopharmaceutical Evaluation for the Metered Dose Transdermal Spray of Dexketoprofen Wangding Lu, Huafei Luo, Zhuangzhi Zhu, Yubo Wu, Jing Luo, and Hao Wang National Pharmaceutical Engineering Research Center, China State Institute of Pharmaceutical Industry, Shanghai 201203, China Correspondence should be addressed to Hao Wang; [email protected] Received 9 October 2013; Revised 22 November 2013; Accepted 26 November 2013; Published 11 February 2014 Academic Editor: Sri Rama K Yellela Copyright © 2014 Wangding Lu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The objective of the present work was to develop a metered dose transdermal spray (MDTS) formulation for transdermal delivery of dexketoprofen (DE). DE release from a series of formulations was assessed in vitro. Various qualitative and quantitative parameters like spray pattern, pump seal efficiency test, average weight per metered dose, and dose uniformity were evaluated. The optimized formulation with good skin permeation and an appropriate drug concentration and permeation enhancer (PE) content was developed incorporating 7% (w/w, %) DE, 7% (v/v, %) isopropyl myristate (IPM), and 93% (v/v, %) ethanol. In vivo pharmacokinetic study indicated that the optimized formulation showed a more sustainable plasma-concentration profile compared with the Fenli group. The antiinflammatory effect of DE MDTS was evaluated by experiments involving egg-albumin-induced paw edema inrats and xylene-induced ear swelling in mice.
    [Show full text]
  • Transdermal Spray in Hormone Delivery
    Yapar & Inal2 Tropical Journal of Pharmaceutical Research March 2014; 13 (3): 469-474 ISSN: 1596-5996 (print); 1596-9827 (electronic) © Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria. All rights reserved. Available online at http://www.tjpr.org http://dx.doi.org/10.4314/tjpr.v13i3.23 Review Article Transdermal Spray in Hormone Delivery Evren Algın-Yapar1* and Özge İnal2 1The Ministry of Health of Turkey, Turkish Medicines and Medical Devices Agency, Söğütözü Mahallesi, 2176. Sokak No. 5, 06520 Çankaya-Ankara, 2Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Ankara, 06100 Tandoğan- Ankara, Turkey *For correspondence: Email: [email protected], [email protected]; Tel: +90 0532 382 56 86 Received: 23 July 2012 Revised accepted: 15 February 2014 Abstract This review examines advances in hormone delivery, particularly using transdermal spray. Transdermal gels, emulsions, patches, subcutaneous implants and sprays have been developed for transdermal hormone therapy in recent years. Transdermal sprays, in their general form of metered-dose transdermal spray, possess major advantages such as enhanced passive transdermal drug delivery with little or no skin irritations, improved cosmetic acceptability, dose flexibility, uniform distribution on the application site and ease of manufacture, and have thus assumed significant importance in hormone delivery. Estradiol, nestrone, testosterone and hydrocortisone aceponate are some of the drugs prepared as metered-dose
    [Show full text]
  • FEP® Blue Focus Formulary (907)
    FEP® Blue Focus Formulary (907) Effective January 1, 2022 The FEP formulary includes a preferred drug list which is comprised of Tier 1, generics and Tier 2, preferred brand-name drugs, preferred generic specialty drugs, and preferred brand-name specialty drugs. Ask your physician if there is a generic drug available to treat your condition. If there is no generic drug available, ask your physician to prescribe a preferred brand-name drug. The preferred brand-name drugs within our formulary are listed to identify medicines that are clinically appropriate and cost-effective. Click on the category name in the Table of Contents below to go directly to that page INTRODUCTION ........................................................................................................................................................................................................................ 5 PREFACE ................................................................................................................................................................................................................................... 5 PRIOR APPROVAL ................................................................................................................................................................................................................... 5 QUANTITY LIMITATIONS ........................................................................................................................................................................................................
    [Show full text]
  • Topical and Transdermal Drug Products
    STIMULI TO THE REVISION PROCESS Stimuli articles do not necessarily reflect the policies Pharmacopeial Forum 750 of the USPC or the USP Council of Experts Vol. 35(3) [May–June 2009] Topical and Transdermal Drug Products The Topical/Transdermal Ad Hoc Advisory Panel for the USP Performance Tests of Topical and Transdermal Dosage Forms: Clarence T. Ueda (Chair), Vinod P. Shah (USP Scientific Liaison), Kris Derdzinski, Gary Ewing, Gordon Flynn, Howard Maibach, Margareth Marques (USP Scientific Liaison),a Howard Rytting,b Steve Shaw, Kailas Thakker, and Avi Yacobi. ABSTRACT This Stimuli article provides general information about the test methods that should be employed to ensure the quality and performance of topical and transdermal drug products. The term topical drug products refers to all formulations applied to the skin except transdermal delivery systems (TDS) or transdermal patches that will be addressed separately. INTRODUCTION Therefore, the in vitro release test for those products also may differ significantly and may require different Drug products topically administered via the skin fall types of apparatus. At present, a product performance into two general categories, those applied for local action test exists only for semisolid formulations, specifically and those for systemic effects. Local actions include creams, ointments, and gels. That test employs the ver- those at or on the surface of the skin, those that exert tical diffusion cell (VDC) system. The VDC system is sim- their actions on the stratum corneum, and those that ple to operate and yields reliable and reproducible results modulate the function of the epidermis and/or the der- when employed by properly trained laboratory person- mis.
    [Show full text]
  • Time for Change in Medicines, 100 Testimonials on Physical Chemistry Relief Curing!
    Time for change in Medicines, 100 testimonials on Physical Chemistry Relief Curing! Testimonial #0 Chiquita: Skin Clearing, Psoriasis Two years ago one of my best friends was trying to get pregnant. Her and her husband had been trying for about 6 months when he came down with a severe break out of psoriasis. They were unable to get rid of it. I had been given a sample of "Pico Skin Relief" to try and had not used any. I thought what we had to loose. So I gave it to them to try. He suds up and sat in the shower for 30 mins before rising off. He then applied a thin coating on just the worst spots. He used it every day like this for 2 weeks. Honest to goodness the next day the psoriasis started fading. Within 2 weeks his skin was soft and no longer red and swollen. They now are proud parents of a baby boy. This soap is a miracle. He has not had another break out since. Thank you so much. Chiquita Testimonial #1 Jeanine: Skin Clearing, Heal Painful Lesions, Now I Have Soft Skin, Pulls Out Sub-Dermal Debris This "Pico Skin Relief" has become a valuable asset in my skin clearing efforts. It helps heal painful lesions. This 1st couple of days I used it I had a new rash that itched and was cleared in 2 days. The "Pico Skin Relief" leaves the skin soft and does not dry it out as some other helps do. Also, it seems to pull out sub-dermal debris like the black dots.
    [Show full text]
  • Preparation and the Biopharmaceutical Evaluation for the Metered Dose Transdermal Spray of Dexketoprofen
    Hindawi Publishing Corporation Journal of Drug Delivery Volume 2014, Article ID 697434, 12 pages http://dx.doi.org/10.1155/2014/697434 Research Article Preparation and the Biopharmaceutical Evaluation for the Metered Dose Transdermal Spray of Dexketoprofen Wangding Lu, Huafei Luo, Zhuangzhi Zhu, Yubo Wu, Jing Luo, and Hao Wang National Pharmaceutical Engineering Research Center, China State Institute of Pharmaceutical Industry, Shanghai 201203, China Correspondence should be addressed to Hao Wang; [email protected] Received 9 October 2013; Revised 22 November 2013; Accepted 26 November 2013; Published 11 February 2014 Academic Editor: Sri Rama K Yellela Copyright © 2014 Wangding Lu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The objective of the present work was to develop a metered dose transdermal spray (MDTS) formulation for transdermal delivery of dexketoprofen (DE). DE release from a series of formulations was assessed in vitro. Various qualitative and quantitative parameters like spray pattern, pump seal efficiency test, average weight per metered dose, and dose uniformity were evaluated. The optimized formulation with good skin permeation and an appropriate drug concentration and permeation enhancer (PE) content was developed incorporating 7% (w/w, %) DE, 7% (v/v, %) isopropyl myristate (IPM), and 93% (v/v, %) ethanol. In vivo pharmacokinetic study indicated that the optimized formulation showed a more sustainable plasma-concentration profile compared with the Fenli group. The antiinflammatory effect of DE MDTS was evaluated by experiments involving egg-albumin-induced paw edema inrats and xylene-induced ear swelling in mice.
    [Show full text]
  • Formulation and Evaluation of Transdermal Gel of Ibuprofen: Use of Penetration Enhancer and Microneedle
    Iranian Journal of Pharmaceutical Sciences 2020: 16 (3):11-32 www.ijps.ir Original Article Formulation and Evaluation of Transdermal Gel of Ibuprofen: Use of Penetration Enhancer and Microneedle Rabinarayan Parhia*, Sahukara Venkata Sai Goutamb, Sumanta Mondalc aDepartment of Pharmaceutical Sciences, Assam University ( A Central University), Silchar-788011, Assam, India, bDepartment of Pharmaceutics, GITAM Institute of Pharmacy, GITAM (Deemed to be University), Gandhi Nagar Campus, Rushikonda, Visakhapatnam-530045, Andhra Pradesh, India, cDepartment of Pharmaceutical chemistry, GITAM Institute of Pharmacy, GITAM (Deemed to be University), Gandhi Nagar Campus, Rushikonda, Visakhapatnam-530045, Andhra Pradesh, India. Abstract The objective of the current study was to develop Ibuprofen (IBP) gel using different polymers individually and in combination and then to select best gel formulation based on various in-vitro evaluation parameters such as bioadhesive strength, gel strength, spreadability, viscosity and drug release study. The selected gel formulation was found to be composed of 1% (w/w) each of hydroxypropyl methylcellulose (HPMC K100M) and sodium carboxy methylcellulose (NaCMC). Two techniques such as chemical method using 1,8-cineole as chemical penetration enhancer (CPE) and physical technique using microneedle were employed to improve IBP permeation across the abdominal skin of rat. Out of the two techniques, the later technique showed higher (2.865-fold) permeation enhancement compared to control. Furthermore, a synergistic effect was also observed when both the techniques were used simultaneously with 3.307-fold increase in permeation enhancement. In- vivo anti-inflammatory study on rats induced with carrageenan paw oedema and analgesic activity investigation by tail flick method in rat model exhibited sustained effect up to 8 h compared to orally treated group.
    [Show full text]